Clinical Trials Logo

Refractory Burkitt Lymphoma clinical trials

View clinical trials related to Refractory Burkitt Lymphoma.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT04285268 Withdrawn - Clinical trials for Refractory Diffuse Large B-Cell Lymphoma

Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Start date: May 6, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well rituximab, venetoclax, and bortezomib work in treating patients with diffuse large B-cell lymphoma that has come back (relapsed) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as rituximab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Venetoclax and bortezomib may stop the growth of tumor cells by blocking some of the proteins needed for cell growth. Giving rituximab, venetoclax, and bortezomib may slow or stop the growth of cancer cells in patients with diffuse large B-cell lymphoma.